Clearmind licenses psychedelic compounds for mental disorders
Pharmaceutical Technology
APRIL 18, 2024
Clearmind Medicine has entered into a licensing agreement with Yissum to develop Generation 3.0 psychedelic compounds for mental disorders.
Licensing Related Topics 
Specialised Therapeutics partners with Treeway to license ALS drug
Pharmaceutical Technology
AUGUST 28, 2023
Specialised Therapeutics has entered into a licensing agreement with Treeway for TW001, designed for treating amyotrophic lateral sclerosis.
Licensing 
246
246 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Almirall licenses IL-21 antibody from Novo Nordisk
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
Licensing 241
241 
Anocca signs licensing deal for EmendoBio’s gene-editing tech
Pharmaceutical Technology
MARCH 15, 2024
Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.
Gene Editing 244
244 
Biogen licenses a stroke drug from Japanese drugmaker TMS
Bio Pharma Dive
MAY 12, 2021
The drug, which Biogen had an option to license, is one of two in the biotech's pipeline for a condition that has had few new treatments developed.
Licensing 246
246 
Novo sheds kidney drug licensed for $1.3bn a year ago
pharmaphorum
NOVEMBER 7, 2024
Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3
Licensing 105
105 
uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS
Pharmaceutical Technology
JANUARY 31, 2023
Gene therapy company uniQure has entered into a global licensing agreement with Apic Bio for APB-102 to treat patients with amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1). The post uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS appeared first on Pharmaceutical Technology.
Gene Therapy 277
277 
J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem
Pharmaceutical Technology
DECEMBER 28, 2023
J&J has acquired a global license for South Korean LegoChem’s ADC for $100m upfront along with milestone-based payments and tiered royalties.
Licensing 245
245 
Investors put $400M into biotech licensing obesity drugs from China
Bio Pharma Dive
MAY 16, 2024
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
Licensing 356
356 
Kite and Daiichi Sankyo update cell therapy licensing agreement
Pharmaceutical Technology
DECEMBER 8, 2022
The post Kite and Daiichi Sankyo update cell therapy licensing agreement appeared first on Pharmaceutical Technology. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Licensing 305
305 
TN govt appoints M N Sridhar as state licensing authority & controlling authority for DC department
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 26, 2024
The Tamil Nadu government has appointed the incumbent controlling authority (CA) of the drugs control administration, M N Sridhar, as state licensing and controlling authority (SLA and CA) for the department of drugs control from June 18 onwards.
Licensing 231
231 
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
Bio Pharma Dive
AUGUST 6, 2024
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
Licensing 332
332 
Merck pays $250M to license Moderna cancer vaccine
Bio Pharma Dive
OCTOBER 12, 2022
The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release.
Vaccine 322
322 
Centre to amend MDR to detail timelines related to medical devices manufacturing license
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 24, 2024
In order to better streamline the approval process for manufacturing license to the medical devices units, the Central government is looking at amending the relevant rules in the Medical Device Rules (MDR), 2017 to include various timelines related to grant of manufacturing license to the four classes of medical devices in the country.
Licensing 189
189 
How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing
Drug Patent Watch
DECEMBER 12, 2024
Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.
Licensing 96
96 
CDSCO releases draft standard evaluation protocols for issuing license for IVDs
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 8, 2025
The Central Drugs Standard Control Organisation (CDSCO) and Indian Council of Medical Research (ICMR) have together released the draft standard evaluation protocols for the purpose of issuing license for in-vitro diagnostics (IVDs) under the Medical Devices Rules (MDR), 2017.
Licensing 180
180 
Ayush Ministry to amend D&C Rules mandating cGMP for homoeopathic drug manufacturing license
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 13, 2024
The Union Ministry of Ayush will soon amend the Drugs and Cosmetic Rules, 1945 to mandate good manufacturing practices for Homoeopathy drug manufacturing, stipulating procedures for loan licensing in the system of Homoeopathy and specifying timelines for issuance of license, among others.
Licensing 189
189 
Voyager licenses gene therapy tools to Novartis
Bio Pharma Dive
MARCH 6, 2023
The Swiss drugmaker's decision is the latest in a string of partnership announcements for the gene therapy maker, which aims to bounce back from past research failures.
Gene Therapy 274
274 
CDSCO reminds medical device firms to pay retention fee to continue holding licenses & certificates
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 23, 2024
The Central Drugs Standard Control Organisation (CDSCO) has requested all stakeholders in the medical devices sector to deposit the requisite fee for retention of license or registration certificate under the Medical Devices Rules (MDR), 2017, well before the stipulated timeline in order to avoid cancellation of the approvals.The drug regulator, in (..)
Licensing 189
189 
GSK to pay $300M to license drug it sees as potential lupus treatment
Bio Pharma Dive
OCTOBER 29, 2024
The licensing deal with China’s Chimagen Biosciences is the latest example of drugmaker interest in exploring the potential of “T cell engagers” in autoimmune disease.
Licensing 176
176 
AB2 Bio and Nippon Shinyaku enter Tadekinig alfa licensing deal
Pharmaceutical Technology
JANUARY 28, 2025
AB2 Bio has made an option and licensing agreement with Nippon Shinyaku, granting the latter the option to commercialise Tadekinig alfa.
Licensing 162
162 
Large pharma drug licensing from China hits high at 28% in 2024
Pharmaceutical Technology
APRIL 1, 2025
Total deal value of innovator drug licensing agreements involving Chinese biopharma licensors has risen 66% to $41.5 billion in 2024.
Licensing 147
147 
Licensing regime posing challenge to micro and small medical devices industry: SMTA
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 25, 2024
The Central government’s actions to mandate licensing of all medical devices is posing a challenge to the industry, especially the micro and small enterprises in the sector, says the Surgical Manufacturers and Traders Association (SMTA), the pan India organisation of manufacturers and traders of surgical equipment for healthcare services providers (..)
Licensing 189
189 
Merck agrees to license COVID-19 pill widely through pact with patent group
Bio Pharma Dive
OCTOBER 27, 2021
The deal with the Medicines Patent Pool is meant to increase access in lower-income countries to molnupiravir, an experimental drug that could become the first oral treatment for COVID-19.
Licensing 326
326 
EditCo Bio secures access to Promega’s technologies in licensing deal
Pharmaceutical Technology
APRIL 23, 2025
EditCo Bio has entered a licensing agreement to secure access to Promegas protein-tagging and bioluminescent identification technologies.
Licensing 130
130 
Takeda pays $300M to license Protagonist drug for blood disorder
Bio Pharma Dive
FEBRUARY 1, 2024
The agreement gives Protagonist an experienced hand in Takeda, which can help the former commercialize its product.
Licensing 284
284 
Centralisation of drug licensing may not be the right path to improve quality of drugs: SPIC
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 20, 2023
Empowering of the Central Drugs Standard Control Organisation (CDSCO) through centralisation of drug licensing may not be the path to improve the quality of drugs manufactured in the country both for domestic and international markets, says SME Pharma Industries Confederation (SPIC), the apex organisation of small and medium pharma industries in the (..)
Licensing 189
189 
GSK to license Elsie’s oligonucleotide discovery platform
Pharmaceutical Technology
FEBRUARY 15, 2024
GSK has exercised its option for a licence for Elsie Biotechnologies’ discovery platform to detect and develop new oligonucleotides.
Licensing 240
240 
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Pharmaceutical Technology
JANUARY 13, 2025
Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the treatment of IPF.
Licensing 147
147 
Catalyst licenses Santhera Pharma’s vamorolone in North America
Pharmaceutical Technology
JUNE 20, 2023
Santhera Pharmaceuticals and Catalyst Pharmaceuticals have signed an exclusive licence and collaboration deal for Santhera’s vamorolone in the US, Canada and Mexico. Catalyst Pharmaceuticals will gain exclusive rights to commercialise vamorolone across the region.
Licensing 246
246 
China-based biotech licenses Sanofi's RNA drug technology
Bio Pharma Dive
JULY 25, 2022
The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.
RNA 246
246 
Biohaven licenses Hangzhou Highlightll’s BHV-8000 to treat brain disorders
Pharmaceutical Technology
MARCH 23, 2023
Biohaven has purchased the exclusive global rights for oral, brain-penetrant dual Tyrosine Kinase 2 (TYK2)/Janus Kinase 1 (JAK1) inhibitor, BHV-8000 (previously TLL-041), which treats immune-mediated brain disorders , from Hangzhou Highlightll Pharmaceutical.
Licensing 263
263 
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
Bio Pharma Dive
NOVEMBER 19, 2024
Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug. The agency turned back Astellas’ attempt to update its drug Izervay’s labeling.
Licensing 144
144 
Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab
Pharmaceutical Technology
NOVEMBER 20, 2024
Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab for malignant ascites.
Licensing 130
130 
MaxCyte and Kamau Therapeutics sign platform license agreement
Pharmaceutical Technology
SEPTEMBER 17, 2024
MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.
Licensing 130
130 
Sanofi licenses fourth NK cell engager from Innate Pharma
Pharmaceutical Technology
DECEMBER 19, 2023
Sanofi and Innate’s cancer collaboration agreement stretches back to 2016, with two of Sanofi’s NK cell engagers in clinical studies.
Licensing 245
245 
Sanofi signs radioligand therapy licensing deal for rare cancers
Pharmaceutical Technology
SEPTEMBER 13, 2024
Sanofi has signed a licensing agreement with RadioMedix and Orano Med to advance a radioligand therapy, AlphaMedix.
Licensing 130
130 
XtalPi’s AI biologics discovery platform licensed to Janssen Biotech
Pharmaceutical Technology
OCTOBER 11, 2024
XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics development.
Licensing 130
130 
With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt
Bio Pharma Dive
JUNE 24, 2021
The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena.
Licensing 324
324 
Licensing agreements for innovator GLP1R drugs weigh in with over $6.2bn in 2024
Pharmaceutical Technology
AUGUST 21, 2024
Innovator drugs targeting GLP1R witnessed a 595% increase in total licensing agreement deal value from 2019 to 2024 YTD.
Licensing 130
130 
Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan
Pharmaceutical Technology
FEBRUARY 9, 2024
Nippon will pay $10m upfront and up to $275m in milestone-based payments for the developmental and commercial rights to Vicore’s C21 in Japan.
Licensing 227
227 
Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal
Fierce Pharma
NOVEMBER 8, 2024
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth up to | Alteogen will use its human hyaluronidase hybridization platform to develop a subcutaneous formulation of the blockbuster antibody-drug conjugate.
Licensing 137
137 
GSK targets neurodegenerative diseases with latest licensing deal
Bio Pharma Dive
APRIL 7, 2025
The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.
Licensing 167
167 
FDA sends signal with tough questions of Lilly at cancer drug meeting
Bio Pharma Dive
FEBRUARY 10, 2022
The agency criticized Eli Lilly for using a trial run in China to seek approval of an immunotherapy it licensed from Innovent Biologics. Outside advisers agreed in a decisive vote that could have repercussions for several other drugmakers.
Licensing 341
341 
Let's personalize your content